Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Liquidia Corporation’s Chief Development Officer, Sanjeev Khindri, filed a Form 3 disclosing his initial beneficial ownership in the company. He is reported as directly beneficially owning 36,992 shares of common stock, tied to restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These 36,992 RSUs were granted on February 10, 2025, with 25% scheduled to vest approximately one year after the grant date and the remaining units vesting ratably on a quarterly basis over the following three years. As of the Form 3 filing date, none of these RSUs have vested.
Liquidia Corporation filed a current report stating that it has issued a press release with its preliminary financial results for the quarter ended December 31, 2025 and a corporate update. The company furnished this press release as Exhibit 99.1 to the filing, indicating that the details are provided for informational purposes and are not deemed filed under certain liability provisions of the securities laws.
Liquidia Corp (LQDA) reported an insider equity transaction by its Chief Business Officer on a Form 4. On 11/18/2025, the officer exercised stock options to acquire a total of 35,656 shares of common stock at an exercise price of $5.89 per share and then sold 35,656 shares of common stock in a market transaction. The sale price was a volume-weighted average of $30.0289 per share for trades between $30.00 and $30.15, executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025.
Following these transactions, the officer beneficially owned 174,998 shares of Liquidia common stock directly. This amount includes unvested restricted stock units granted in 2023, 2024 and 2025, as well as shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia (LQDA) insider transaction: The company’s Chief Accounting Officer reported two open‑market sales of common stock on 11/07/2025. The sales were 8,342 shares at $25.16 and 20,662 shares at $25.06. Following these transactions, the reporting person beneficially owned 155,334 shares, held directly.
Footnote details list unvested and plan-related holdings, including 1,884 unvested RSUs from a 01/16/2022 grant, 15,625 unvested RSUs from a 01/25/2023 grant, 32,110 unvested RSUs from a 01/11/2024 grant, 50,861 RSUs granted on 01/11/2025 (none vested), 25,000 RSUs granted on 07/01/2025 (none vested), and 3,527 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corporation (LQDA) filed a Form 4 showing stock sales by Chief Medical Officer Dr. Rajeev Saggar. On 11/05/2025, he sold 4,918 shares of common stock at $27 and 66,463 shares at $27. Following these transactions, his beneficial ownership stood at 176,549 shares, held directly.
The filing notes equity awards and purchases: 26,041 unvested RSUs from an 83,333 grant dated January 11, 2023; 31,777 unvested RSUs from a 56,492 grant dated January 11, 2024; and 71,780 RSUs granted on January 11, 2025, none of which had vested as of the filing date. It also includes 2,221 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corporation reported its Q3 2025 results, driven by the first full quarter of YUTREPIA commercialization. Total revenue reached $54.3 million, up from $4.4 million a year ago, including $51.7 million in product sales from YUTREPIA and $2.7 million in service revenue from the Sandoz promotion agreement.
The company generated $1.8 million of operating income as higher sales offset elevated selling, general and administrative costs of $40.1 million. Net loss narrowed to $3.5 million (basic and diluted EPS $(0.04)), primarily due to $6.9 million in interest expense that outweighed $1.6 million in interest income.
As of September 30, 2025, cash and cash equivalents were $157.5 million, with long‑term debt (including current portion) of $192.5 million. Shares outstanding were 86,819,212. YUTREPIA was FDA‑approved on May 23, 2025 for PAH and PH‑ILD and launched June 2, 2025, underpinning the quarter’s product revenue. Management noted minimum cash covenants of $15.0 million under its revenue interest financing agreement and stated it has sufficient liquidity for at least the next twelve months.
Liquidia Corporation reported its Q3 2025 results, driven by the first full quarter of YUTREPIA commercialization. Total revenue reached $54.3 million, up from $4.4 million a year ago, including $51.7 million in product sales from YUTREPIA and $2.7 million in service revenue from the Sandoz promotion agreement.
The company generated $1.8 million of operating income as higher sales offset elevated selling, general and administrative costs of $40.1 million. Net loss narrowed to $3.5 million (basic and diluted EPS $(0.04)), primarily due to $6.9 million in interest expense that outweighed $1.6 million in interest income.
As of September 30, 2025, cash and cash equivalents were $157.5 million, with long‑term debt (including current portion) of $192.5 million. Shares outstanding were 86,819,212. YUTREPIA was FDA‑approved on May 23, 2025 for PAH and PH‑ILD and launched June 2, 2025, underpinning the quarter’s product revenue. Management noted minimum cash covenants of $15.0 million under its revenue interest financing agreement and stated it has sufficient liquidity for at least the next twelve months.
Liquidia Corporation furnished a Current Report announcing it issued a press release with financial results for the quarter ended September 30, 2025, and provided a corporate update.
The press release is included as Exhibit 99.1. The information under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act.
Liquidia Corporation furnished a Current Report announcing it issued a press release with financial results for the quarter ended September 30, 2025, and provided a corporate update.
The press release is included as Exhibit 99.1. The information under Item 2.02 is expressly stated as furnished and not deemed filed under the Exchange Act.
Liquidia Corporation entered an exclusive license with Vectura Limited to develop, manufacture and commercialize in the United States treprostinil products, including Liquidia’s L606, administered via Vectura’s nebulizer device for PAH and PH‑ILD. Vectura will manufacture and supply clinical and commercial devices.
Financial terms include an upfront $2,000,000 payment, development milestones of up to $12,000,000, sales milestones of up to $92.5 million, and royalties at middle single‑digit rates on U.S. sales. Liquidia also secured rights of first negotiation for additional territories and indications. The agreement continues on a country‑ and product‑specific basis through the applicable royalty term and includes customary termination rights for breach, bankruptcy, program discontinuation, feasibility determinations, related agreement terminations, effort requirements, and patent challenges.
Liquidia Corporation (LQDA) Chief Business Officer filed a Form 4 reporting a sale of 692 shares of common stock at $22.93 on October 27, 2025, executed pursuant to a Rule 10b5-1 plan adopted on December 15, 2023. The filing states the shares were sold to cover taxes tied to the settlement of RSUs granted on July 6, 2023.
Following the transaction, the officer beneficially owned 174,998 shares directly. Holdings include 10,937 unvested RSUs from the July 6, 2023 grant, 22,268 unvested RSUs from a January 11, 2024 grant, and 61,895 RSUs granted on January 11, 2025 (none vested as of the filing date), plus 11,586 shares acquired under the 2020 Employee Stock Purchase Plan.
Liquidia Corp (LQDA) reported an insider transaction on a Form 4. The Chief Accounting Officer sold 1,073 shares of common stock at $22.93 per share on 10/27/2025 (transaction code S).
The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted on December 15, 2023 and was executed to cover taxes associated with the settlement of previously granted RSUs. Following the transaction, the reporting person beneficially owns 184,338 shares, held directly.